Gender (male) (Nr., %) |
31 (44.9%) |
Age (mean ± SD, median (IQR)) |
60.51 ± 16.7, 62 (49.5–75) |
Septic shock (Nr., %) |
27 (39.1%) |
WBC (mean ± SD, median (IQR)) |
16,390 ± 4680, 15.4 (13,411–18,560) |
CRP (mean ± SD, median (IQR)) |
152.96 ± 107.04, 113 (82.5–214) |
Procalcitonin (mean ± SD, median (IQR)) |
5.41 ± 8.49, 2.68 (0.8–5.4) |
ASA Grading (Nr., %) |
|
I |
2 (2.9%) |
II |
37 (53.6%) |
III |
13 (18.8%) |
IV |
14 (20.3%) |
V |
3 (4.3%) |
Comorbidities (Nr., %)
|
29 (42%) |
Cardiovascular diseases (Nr., %) |
29 (42%) |
Diabetes mellitus type II (Nr., %) |
3 (4.3%) |
Modified Hinchey classification (Nr., %) |
|
IIA |
17 (24.6%) |
IIB |
30 (43.5%) |
III |
15 (21.7%) |
IV |
7 (10.1%) |
Source control (Nr., %) |
|
Laparoscopic drainage |
30 (43.5%) |
Laparoscopic resection + anastomosis |
12 (17.4%) |
Laparoscopic Hartmann |
6 (8.7%) |
Open resection + anastomosis |
3 (4.3%) |
Open Hartmann |
18 (26.1%) |
Identified pathogens (Nr., %) |
48 (69.6%) |
ICU admission (mean ± SD, median (IQR))
|
1.72 ± 1.4, 1 (1–2) |
ICU admission > 1 day (Nr., %) |
27 (39.1%) |
LOS (mean ± SD, median (IQR)) |
7.87 ± 2.97, 8 (6–10) |
LOS < 7 days |
25 (36.2%) |
LOS 7–10 days |
31 (44.9%) |
LOS > 10 days |
13 (18.8%) |
Empiric antibiotherapy–adequate (Nr., %) |
36 (75%) |
Mortality (Nr., %) |
4 (5.8%) |